Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myocet, Taxotere, and Herceptin as Primary Chemotherapy in HER2+ Breast Cancer
NCT00129896Phase 2Completed
- Sponsor
- GEICAM
- Start
- Jan 2004
- Primary completion
- Dec 2008
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in breast cancer, sponsored by GEICAM. Primary endpoints: Recommended Doses of the combination treatment up to 24 months and Pathological Complete Response up to 24 months. Started Jan 2004; status: completed.
02
Drugs
doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00129896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129896.